Jefferson E. Davis - Mar 14, 2023 Form 4 Insider Report for Acer Therapeutics Inc. (ACER)

Role
Chief Business Officer
Signature
/s/ Harry S. Palmin, Attorney-in-Fact
Stock symbol
ACER
Transactions as of
Mar 14, 2023
Transactions value $
$0
Form type
4
Date filed
3/16/2023, 04:32 PM
Previous filing
Jan 19, 2022
Next filing
Nov 20, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACER Employee Stock Option (right to buy) Award $0 +30K $0.00 30K Mar 14, 2023 Common Stock 30K $1.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option, which is made as part of the issuer's 2023 annual compensation cycle, vests and becomes exercisable over four years as follows: 25% of the shares vest on March 14, 2024, and the remaining 75% of the shares vest quarterly over the remaining three years.